BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Genetown

  Aktis Oncology To Present At The 40th Annual J.P. Morgan Healthcare Conference

  Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers, announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference, taking place virtually, Jan. 9 - 12.

  January 6, 2022

   · 

  1 min read
• Biotech Bay

  Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

  Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC).

  January 6, 2022

   · 

  7 min read
• Genetown

  Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs

  Anokion SA today reported progress for its clinical-stage programs, KAN-101 and ANK-700.

  January 6, 2022

   · 

  4 min read
• Biotech Bay

  Endpoint Health Presents Published Results from a Retrospective Study of Adult ARDS Patients, Identifying an Innovative Approach to Predicting Clinical Outcomes

  Endpoint Health, Inc. today announced that researchers have identified two new, clinically distinct subgroups (subphenotypes) of adults with acute respiratory distress syndrome (ARDS).

  January 6, 2022

   · 

  7 min read
• Biotech Bay

  Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

  Ambagon Therapeutics today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.

  January 6, 2022

   · 

  4 min read
• Biotech Bay

  Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

  Biomea Fusion, Inc. announced today that BMF-219 displayed remarkable activity in both the Zucker Diabetic Fatty (ZDF) Rat and the Streptozotocin-Induced Diabetes (STZ).

  January 6, 2022

   · 

  6 min read
• Genetown

  Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  Sarepta Therapeutics, Inc. today announced that senior management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 10:30 a.m. E.T. / 7:30 a.m. P.T.

  January 6, 2022

   · 

  2 min read